<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39449663</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>25</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Public Health Benefits of Applying Evidence-Based Best Practices in Managing Patients Hospitalized for COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ciae517</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciae517</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">As COVID-19-related mortality remains a concern, optimal management of patients hospitalized for COVID-19 continues to evolve. We developed a population model based on real-world evidence to quantify the clinical impact of increased utilization of remdesivir, the effectiveness of which has been well established in hospitalized patients with COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The PINC AI healthcare database records for patients hospitalized for COVID-19 from January to December 2023 were stratified by those treated with or without remdesivir ("RDV" and "No RDV") and by supplemental oxygen requirements: no supplemental oxygen charges (NSOc), low-flow oxygen (LFO), and high-flow oxygen/non-invasive ventilation (HFO/NIV). Key vulnerable subgroups such as elderly and immunocompromised patients were also evaluated. The model applied previously published hazard ratios (HRs) to 28-day in-hospital mortality incidence to determine the number of potential lives saved if additional "No RDV" patients had been treated with remdesivir upon hospital admission.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 84,810 hospitalizations for COVID-19 in 2023, 13,233 "No RDV" patients were similar in terms of characteristics and clinical presentation to the "RDV" patients. The model predicted that initiation of remdesivir in these patients could have saved 231 lives. Projected nationally, this translates to &gt;800 potential lives saved (95% CI: 469-1,126). Eighty-nine percent of potential lives saved were elderly and 19% were immunocompromised individuals. Seventy-one percent were among NSOc or LFO patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This public health model underscores the value of initiating remdesivir upon admission in patients hospitalized for COVID-19, in accordance with evidence-based best practices, to minimize lives lost due to SARS-CoV-2 infection.</AbstractText><CopyrightInformation>Â© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kalil</LastName><ForeName>Andre C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>University of Nebraska Medical Center, Omaha, Nebraska, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandak</LastName><ForeName>Aastha</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5653-435X</Identifier><AffiliationInfo><Affiliation>Certara, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Luke S P</ForeName><Initials>LSP</Initials><AffiliationInfo><Affiliation>Imperial College, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahuja</LastName><ForeName>Neera</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolditz</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6022-6827</Identifier><AffiliationInfo><Affiliation>Medical Department I, Division of Pulmonology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casciano</LastName><ForeName>Roman</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-7083-9536</Identifier><AffiliationInfo><Affiliation>Certara, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kadambi</LastName><ForeName>Ananth</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Certara, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaghoubi</LastName><ForeName>Mohsen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Certara, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsiodras</LastName><ForeName>Sotirios</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Professor of Medicine and Infectious Diseases; National &amp; Kapodistrian University of Athens Medical School; Chair, 4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malin</LastName><ForeName>Jakob J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0002-2989-0436</Identifier><AffiliationInfo><Affiliation>Department I of Internal Medicine, Division of Infectious Diseases, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mozaffari</LastName><ForeName>Essy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartoletti</LastName><ForeName>Michele</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1099-3283</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Disease Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">data science</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">real world data</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>4</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39449663</ArticleId><ArticleId IdType="doi">10.1093/cid/ciae517</ArticleId><ArticleId IdType="pii">7840723</ArticleId></ArticleIdList></PubmedData></PubmedArticle>